April 1, 2021Journal of Diabetes
Do SGLT ‐2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
Key result
SGLT-2 inhibitors provide similar cardiovascular benefits in heart failure regardless of HFrEF or HFpEF.
Why the study?
While the beneficial cardiovascular effects of SGLT-2 inhibitors in heart failure are known, whether they exert similar effects in heart failure with reduced versus preserved ejection fraction was unclear.
Do SGLT-2 inhibitors exert similar cardiovascular benefits in patients with heart failure with reduced or preserved ejection fraction?
Population
Patients with heart failure with reduced or preserved ejection fraction
Comparison
SGLT-2 inhibitors across heart failure types
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
May support consistent SGLT-2i CV benefits across HF types; leaves open dedicated HFpEF trials.
Study Design
Type
Meta-Analysis
Structured PICO
Do SGLT-2 inhibitors exert similar cardiovascular benefits in patients with heart failure with reduced or preserved ejection fraction?
P
Population
Patients with heart failure with reduced or preserved ejection fraction
I
Intervention
SGLT-2 inhibitors as a class
O
Outcome
Cardiovascular benefits
This meta-analysis suggests that SGLT-2 inhibitors provide similar cardiovascular benefits across the spectrum of heart failure, regardless of ejection fraction.
Cite This Study
Singh et al. (2021) conducted a meta-analysis in Heart failure with reduced or preserved ejection fraction. SGLT-2 inhibitors was evaluated on Cardiovascular benefits. SGLT-2 inhibitors exerted similar cardiovascular benefits in patients with heart failure irrespective of whether they had reduced or preserved ejection fraction.